Expression of Enhancer of Zeste Homolog 2 (EZH2) Gene in Acute Myeloid Leukemia.
Nahla A M HamedAshraf El GhandourReham Abdel Haleem Abo ElwafaMohamed Rafaat RezkOmar GhallabPublished in: Asian Pacific journal of cancer prevention : APJCP (2023)
Low EZH2 expression is prevalent in Egyptian AML patients subsequently; it is suggested to function as tumor suppressor gene rather than an oncogene. Moreover, EZH2 downregulation is associated with resistance to chemotherapy and high mortality rate.
Keyphrases
- poor prognosis
- long non coding rna
- end stage renal disease
- binding protein
- long noncoding rna
- ejection fraction
- copy number
- genome wide
- newly diagnosed
- chronic kidney disease
- acute myeloid leukemia
- peritoneal dialysis
- cardiovascular events
- prognostic factors
- transcription factor
- squamous cell carcinoma
- type diabetes
- cardiovascular disease
- dna methylation
- risk factors
- coronary artery disease
- acute lymphoblastic leukemia